

Use of lentiviral vectors in vaccination

Min-Wen Ku, Pierre Charneau, Laleh Majlessi

▶ To cite this version:

Min-Wen Ku, Pierre Charneau, Laleh Majlessi. Use of lentiviral vectors in vaccination. Expert Review of Vaccines, 2021, 20 (12), pp.1571 - 1586. 10.1080/14760584.2021.1988854. pasteur-03695112

HAL Id: pasteur-03695112 https://pasteur.hal.science/pasteur-03695112v1

Submitted on 14 Jun2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 Use of Lentiviral Vectors in Vaccination

- 2 Min-Wen Ku, Pierre Charneau, and Laleh Majlessi
- 3
- 4 Institut Pasteur-TheraVectys Joint Lab, Virology Department, 28 rue du Dr. Roux, Paris F-75015, France

5

- 6 Min-Wen Ku, Ph.D, Post-Doctorate
- 7 Pierre Charneau, Ph.D, Head of the Unit
- 8 Laleh Majlessi, Ph.D, Associate Professor

9

10 *Contact: Laleh Majlessi: laleh.majlessi@pasteur.fr, Phone +33 1 40 61 32 68

11

12

13 ABSTRACT (199 words)

Introduction: Lentiviral vectors have emerged as powerful vectors for vaccination, due to their high efficiency to transduce dendritic cells and to induce long-lasting humoral immunity, CD8⁺ T cells, and effective protection in numerous preclinical animal models of infection and oncology.

Areas covered: Here, we reviewed the literature, highlighting the relevance of lentiviral vectors in vaccinology. We recapitulated both their virological and immunological aspects of lentiviral vectors. We compared lentiviral vectors to the gold standard viral vaccine vectors, i.e., adenoviral vectors, and updated the latest results in lentiviral vector-based vaccination in preclinical models.

21 Expert opinion: Lentiviral vectors are non-replicative, negligibly inflammatory, and not targets of pre-22 existing immunity in human populations. These are major characteristics to consider in vaccine 23 development. The potential of lentiviral vectors to transduce non-dividing cells, including dendritic cells, 24 is determinant in their strong immunogenicity. Notably, lentiviral vectors can be engineered to target 25 antigen expression to specific host cells. The very weak inflammatory properties of these vectors allow 26 their use in mucosal vaccination, with particular interest in infectious diseases that affect the lungs or 27 brain, including COVID-19. Recent results in various preclinical models have reinforced the interest of 28 these vectors in prophylaxis against infectious diseases and in onco-immunotherapy.

29

30

31 **KEYWORDS**

Antigen Expression *in vivo*, Humoral Immunity, Lentiviral Vectors, Long-Lasting Immune Memory,
 Non-Integrating Lentiviral Vectors, Transduction, T-Cell Immunity, Vaccination.

34 Article highlights

- Lentiviral vectors have emerged as a particularly powerful vaccinal platform, as they exhibit a
 combined capacity to induce both strong and long-lasting T-cell and humoral immunity.
- Lentiviral vectors are not targets of pre-existing vector-specific immunity in human populations.
- Non-integrating versions of lentiviral vectors are highly immunogenic and circumvent the potential
 genotoxicity associated with the use of integrating vectors.
- The exclusion of all structural and functional HIV genes from the lentiviral genome ensures that the
 resulting vector is replication defective and only expresses the transgene of interest.
- Pseudotyping of lentiviral vectors with the heterologous Vesicular Stomatitis Virus envelope
 Glycoprotein (VSV-G) confers them with broad tropism for various cell types, including dendritic
 cells.
- The potential of lentiviral vectors to transduce non-dividing antigen presenting cells is a favorable
 characteristic for vaccine development.
- 47 Lentiviral vectors can be engineered to transductionally or transcriptionally target antigen expression
 48 to specific host tissue/cells.
- Lentiviral vectors are non-cytopathic and very weakly inflammatory and can therefore be used for
 mucosal vaccination via the nasal route, with a particular interest in infectious diseases that affect the
 lungs or brain.
- Recent results in preclinical models have reinforced the relevance of these vectors in both
 prophylactic vaccination and onco-immunotherapy.

54 1. Introduction

55 Recombinant vector-based vaccine platforms rely on engineered bacteria or viruses for immunization. 56 The concept behind using recombinant vectors is to exploit the natural infectivity and immunological 57 properties of live viruses to elicit excellent immune responses and long-lasting immunity against 58 heterologous antigens. A number of bacterial vectors, such as Mycobacterium bovis BCG, Listeria 59 monocytogenes, Salmonellae spp and Shigellae spp, have been shown to effectively induce both humoral 60 and cell-mediated immunity in animal models. Although essential virulence factors have been deleted 61 from these bacterial vectors, the possibility of competition with indigenous flora, permeant colonization 62 of the gastrointestinal tract, unintentional horizontal gene transfer, and genetic reversion have raised 63 safety concerns about using such vectored vaccines [1]. Among other important heterologous antigen 64 carriers are viral vectors, engineered to remove virulence factors for reasons of safety. Numerous viral 65 vectors have been used for vaccination, including vectors derived from adenoviruses, retroviruses, 66 vaccinia viruses, poxviruses, alphaviruses, and lentiviruses. Viral vectors can be divided into those that 67 are replicative and non-replicative. Non-replicative viruses have been the most widely tested in clinical 68 trials, due to concerns over safety. Similar to bacterial vectors, viral vectors induce strong humoral and 69 cellular immunity. However, only a low dose is required for vaccination with the best viral vectors, which 70 compensates for their high production cost [2]. One of the major drawbacks of the vast majority of viral 71 vectors is the pre-existing vector immunity in human populations. Therefore, viral vectors for vaccination 72 must be selected with care, taking into account their virological, immunological, and epidemiological 73 characteristics [3].

74 Viral vectors for vaccination have been derived from poxviruses, alphaviruses, and adenoviruses [4-7]. 75 Poxviruses, including Modified Vaccinia virus Ankara (MVA), canarypox virus (ALVAC), and New 76 York attenuated Vaccinia virus (NYVAC), were the first viral vectors to be evaluated in clinical trials [8]. 77 The use of poxvirus-based vectors has been complicated due to their limited ability to induce memory T 78 cells and the high prevalence of pre-existing anti-vector immunity in human populations [9,10]. The use 79 of alphavirus-based vectors is also limited because they induce strong transgene expression, leading to 80 high toxicity for the host cells [10]. Compared to poxvirus-based vectors, adenoviral vectors trigger 81 stronger T-cell responses, but these vectors, and especially those based on human adenoviruses, are 82 targets of highly prevalent pre-existing adaptive immunity which reduces their persistence in the host 83 organism and thus decreases their immunogenicity [11]. Increasing the administered dose of an 84 adenoviral vector can improve immunogenicity, but can also cause serious "grade 3" adverse events, as 85 recently demonstrated in a phase 2 trial of an Ad5-vectored COVID-19 vaccine [12]. Although such pre-86 existing immunity can be circumvented by using animal-derived serotypes, there is evidence suggesting 87 that such serotypes are less immunogenic and protective than Ad5 [13,14].

88 Among viral vectors, lentiviral vectors (LVs) have emerged as a particularly powerful platform for 89 vaccination purposes. LVs exhibit several advantages over other viral vectors, including their combined 90 capacity to induce both strong and long-lasting T-cell immunity and antibody responses, without being 91 inflammatory or the target of pre-existing vector-specific immunity [15-19]. LV components, such as the 92 envelope and capsid proteins, can prime vector-specific immunity [20]. However, pre-existing immunity 93 against the LV envelope is rarely found in human populations because LVs are predominantly 94 pseudotyped with the heterologous Vesicular Stomatitis Virus Glycoprotein (VSV-G) envelope, to which 95 the human population has been barely exposed [21]. Pre-existing immunity against the LV capsid is also 96 rare, because infections with lentiviruses are less prevalent than those caused by other viruses commonly 97 used as vectors, such as adenoviruses [22,23]. LVs can be divided into integrating (ILVs) and non-98 integrating (NILVs) categories. ILVs are the vector of choice for gene therapy, whereas NILVs are 99 preferred for vaccination. Both ILVs and NILVs are capable of transducing dividing and non-dividing 100 cells, notably dendritic cells (DCs) [24-26]. LVs are non-replicative, which means that they only support 101 one round of host cell infection. The ability of LVs to transduce Antigen Presenting Cells (APCs) ensures 102 antigen expression throughout the life span of these cells, for instance 5-7 days post-immunization for 103 plasmacytoid DCs [27]. With respect to vector persistence, it must be considered that promoters may play 104 a role, as strong promoters that result in higher antigen expression may also trigger more robust immune 105 responses, in turn capable of eliminating transduced cells that harbor the vector-specific DNA [28]. We 106 showed that ILV harboring a β2-microglobulin promoter remained detectable in mice from a few days to 107 a maximum of three months post-intramuscular immunization, as quantified by a highly sensitive qPCR assay, detecting vector-specific DNA [29]. Others showed that NILVs harboring the cytomegalovirus 108 109 (CMV) promoter, introduced via a single intramuscular injection in rhesus macaques, persisted for at least 110 six months post-immunization at the site of injection [30]. Similar results were obtained with NILV 111 harboring the CMV promoter in mice in which vector-specific DNA was only detected at the injection 112 site, i.e., the muscles, but not at systemic sites, including the spleen and large intestine [31]. Hence, antigen expression and vector persistence vary on a case-by-case basis, depending on: (i) the route of 113 114 vaccination, (ii) the promoter, (iii) the type of cell/tissue, and (iv) type of vector used [32-36]. Similar to 115 adenoviral vectors, LVs are non-replicative and non-cytopathic vectors but unlike adenoviral vectors, 116 LVs are negligibly inflammatory, which largely contributes to their safety and which paves the way for their potential use in mucosal immunization. Overall, these traits make the use of LVs a plausible 117 118 opportunity for further vaccine vector development suitable for various clinical applications.

119 **2. Methods**

We performed a literature review in PubMed using the following keywords: "vaccine", "immunization", "viral vectors", "lentiviral vectors", "safety", "antibody", "immunology", and "T-cell vaccines". Inclusion criteria for manuscript selection were that they: (i) were written in English, (ii) were relevant to viral vectors, (iii) were relevant to LVs, and (iv) had a publication dates between 1991 and February2021.

125 **3. Results**

126 In total, 119 original articles and 40 reviews were selected to extract essential information on the 127 virological, immunological, and vaccinological aspects of LVs. Various features of LVs were also 128 compared to those of the gold standard adenoviral vectors.

129 3.1. Development of LVs

130 Lentiviruses are a subclass of retroviruses, best known for their ability to perform reverse transcription of 131 their single-stranded RNA genome to a double-stranded DNA. Unlike other retroviruses, lentiviruses can 132 infect both dividing and non-dividing cells, providing the possibility to target cell types that are not infectable by other viral vectors [37]. Based on these characteristics, the use of Human Immunodeficiency 133 134 Virus (HIV)-1 was proposed as the blueprint for LV development [38]. Today, most of the LVs are 135 derived from HIV-1, HIV-2, and non-human primate lentiviruses, such as Simian Immunodeficiency 136 Virus (SIV), whereas a minority are derived from Feline Immunodeficiency Virus (FIV) and Equine 137 Infectious Anemia Virus (EIAV) [39].

138 The HIV-1 life cycle and its function rely on three essential genes: gag, pol, and env. The gag gene encodes a structural protein, pol encodes a set of enzymes required for reverse transcription and 139 140 integration into DNA, and *env* encodes for the viral surface protein. In addition to these genes, the HIV-1 genome also contains regulatory tat and rev genes, as well as vif, vpr, vpu, and nef accessory genes. These 141 viral genes are flanked by Long-Terminal Repeats (LTRs) consisting of "U3", "R", and "U5". The LTRs 142 143 are essential for transcription and integration of the viral genome. The transcriptional control elements, 144 such as the promoter and enhancer, are situated in the U3 region of the LTRs [40]. The HIV-1 genome also contains: (i) the packaging signal Ψ , necessary for the recruitment of the viral genome for packaging 145 146 into the budding viral particle, (ii) the central PolyPurine Tract (cPPT) and Central Termination Sequence 147 (CTS), necessary for "DNA flap" formation and nuclear translocation, and (iii) the Rev Response Element (RRE), important for unspliced RNA transport to the cytoplasm (Figure 1A) [40]. The cPPT and 148 149 CTS cis-acting elements are unique to LVs, operating coordinately to form a triple-stranded DNA 150 structure known as a "DNA flap", which is indispensable for the nuclear import process [41]. The absence or mutation of cPPT significantly decreases the infectivity of LVs, resulting in the accumulation 151 of linear DNA at the vicinity of the nuclear membrane. As detailed below, the development of 152 recombinant LVs from the pathogenic HIV-1 has been accompanied by several challenges, including the 153 154 generation of replication-defective LVs and the expansion of the tropism beyond lymphocytes and 155 myeloid cells [42].

156 To produce a replication-defective LV, only viral structural and functional genes imperative for proper 157 LV function are included. These genes are physically separated onto three distinct plasmids encoding for: (i) packaging, (ii) envelope, both acting in trans, and (iii) the cis-acting elements (necessary for entry, 158 reverse transcription, nuclear import, and integration), which are included in the expression cassette of the 159 LV RNA. These cis-acting elements are the Ψ packaging signal, cPPT/CTS, and the RRE, and are 160 161 flanked by two LTRs (Figure 1B) [43]. The exclusion of structural and functional genes from the LV 162 genome ensures that the resulting viral particles are replication defective. An additional safety feature has 163 been introduced into LVs by further deleting the promoter enhancer sequence situated in the U3 region of the 3' LTR (Δ U3 LTR) expression cassette, forming the self-inactivated (SIN) vector. The Δ U3 LTR is 164 duplicated and transferred to the 5' LTR of the pro-viral DNA during reverse transcription, thereby 165 166 abolishing the transcriptional unit in the LTR (Figure 2). This deletion in the 3' LTR also prevents the activation of the promoter, located nearby to the integration site of the vector [43]. 167

To expand the host cell tropism of LVs, the natural HIV-1 envelope has been substituted with VSV-G. The HIV-1 envelope shows restrictive tropism towards lymphocytes and myeloid cells, hence precluding the transduction of other cell types. By contrast, VSV-G shows broad tropism, infecting a wide range of cells, including APCs [21]. VSV-G pseudotyping also increases LV stability and provides the possibility to concentrate the vector for applications that require high viral particle titers [44].

173 3.2. Non-Integrating LVs

174 The integrating nature of viral vectors is a double-edged sword; beneficial for long-term transgene expression, it is potentially detrimental with the possibility of inducing oncogenesis. One serious adverse 175 176 effect of viral vector integration was observed in a clinical trial using a Murine Leukemia Virus (MLV)-177 based retroviral vector to correct X-linked Severe Combined Immunodeficiency Disease (SCID). The insertional mutagenesis caused by MLV, near the LMO-2 proto-oncogene led to malignancy in several 178 179 participants in the clinical trial [45,46]. Unlike MLV, to date, no serious adverse effects have been observed with LV-mediated clinical studies [47]. Detailed profiling of the integration sites of LV and 180 181 MLV has been performed to better understand vector safety. These studies revealed a non-random 182 integration profile for both vectors, with LVs preferentially integrating near transcriptional units, whereas MLV display a bias towards transcriptional start sites [47]. LVs also exhibit additional criteria for 183 184 integration site selection, such as favoring recognition sites of cellular factors, i.e., Lens Epithelium-185 Derived Growth Factor (LEDGF/p75), Barrier-to-Autointegration Factor (BAF), and High-Mobility 186 Group (HMG), which interact with the pre-integration complex of LVs [47,48]. In comparison, MLV was 187 found to cluster preferentially near the enhancer sequence of proto-oncogenes [49]. These studies showed 188 that the integration sites of LVs do not favor the activation of proto-oncogenes and that they are a safer 189 choice for clinical use.

190 Despite many studies demonstrating the excellent safety profile of ILVs, the concern of insertional 191 mutagenesis prompted the development of NILVs. NILVs carry a missense amino acid in the catalytic triad of the integrase, that prevents the integration of viral DNA into the host chromosome. The most 192 commonly reported mutations affecting the catalytic triad are at the D64, D116, and E152 mutation sites 193 194 [50]. Without integration, the viral DNA remains in an episomal form, bearing either one or two LTRs, both equally effective in gene expression. The lack of integration signifies the eventual loss of the 195 196 transgene during cell division, which affects the overall transgene level [51]. However, in non-dividing cells, the transgene expression remains comparable for ILV and NILV, due to the fact that the transgene 197 198 is not diluted out by cell division, as shown in muscles and DCs [52,53]. The lack of integration does not 199 hamper the induction of an effective immune response and only requires adjustment of the vector dose 200 [17]. A comparison of ILVs and NILVs with various antigens in preclinical models showed that with 10 times more NILV the same immunization efficiency can be achieved with 10 times more NILV as with 201 ILV; a dose of 1×10^8 Transduction Unit (TU)/animal is optimal for NILV, versus 1×10^7 TU/animal for 202 ILV [54,55]. 203

204 3.3. Advantages of LVs as vaccine vectors

The capability of LV to transduce non-dividing cells, and notably DCs and macrophages, is a favorable characteristic for vaccine development. The ability to efficiently replicate in non-dividing cells is due to the fact that the genome of lentiviruses can be imported into the nucleus, independent of mitosis. This is a distinctive property of LVs, as other retroviral vectors transduce only dividing cells because they are unable to cross the nuclear membrane, except during cell division [56]. Taking advantage of their active nuclear import by lentiviruses, LVs are also used as a gene delivery vectors to target non-dividing cells such as neurons and glia, for genetic correction [57].

212 Another advantage of LVs is the quasi absence of pre-existing immunity against them in the human populations, which is linked to their: (i) pseudotyping with VSV-G, an envelope glycoprotein to which 213 humans are rarely exposed to and (ii) the low prevalence of lentivirus infection in humans. The presence 214 215 of pre-existing humoral vector immunity can limit the number of transduced cells, impeding APC transduction, antigen expression, and thus induction of immune responses against the encoded antigens. 216 217 The presence of pre-existing T-cell vector immunity may rapidly eliminate transduced APCs expressing the antigen. Several studies using viral vectors have reported the negative impact of pre-existing 218 219 immunity on the induction of cellular and humoral responses. This is, particularly, a limitation for the initial administration of Ad5 and herpes simplex virus type 1 vectors, which have high seroprevalence in 220 the human population [45]. In vaccination, multi-dose administration of vectors is important to reinforce 221 the immune response. However, envelope-specific neutralizing antibodies triggered during the initial LV 222 223 injection would likely blunt repeated administration of LVs with the same envelope glycoprotein.

However, anti-envelope immunity can be overcome by pseudotyping LV with heterologous VSV-G serotypes, without impeding the efficacy of the vector, as demonstrated previously for ILVs and NILVs [15,17,30,58,59].

227 LVs can accommodate large transgenes of up to in the range of 5 to 7 kb, which further extends the scope of their application, for example in the generation of multi-antigenic vaccines [60]. Large transgenes 228 229 exceeding 10 kb have been reported [60,61]. However, the accommodation of large transgenes may come 230 at the cost of lower functional viral titers, as previous studies showed a semi-logarithmic reduction of 3 to 231 4 folds in functional LV titer per kb increase in genome size [60,62]. Aside from these major advantages, 232 LVs are negligibly inflammatory and induce only minute levels of phenotypic and functional DC 233 maturation *in vitro* and *in vivo* [63] and our unpublished data. This property largely contributes to the 234 safety of these vectors and makes their use possible in mucosal applications for vaccination [54,55].

235 3.4. Limitations of LV

236 Large-scale production and purification of viral vectors are often the bottlenecks to successful gene 237 therapies and vaccination development. Each viral vector presents its own sets of manufacturing 238 problems, and LVs are no exception to this [64-66]. The upstream process of LV production involves the transfection of plasmids into packaging cells to produce vector particles. Laboratory-scale LV production 239 240 is achieved via transiently co-transfection of HEK293T cells, which is economically and technically 241 challenging to scale up for large- or industrial-scale production. Several factors that can limit the 242 productivity of LVs in upstream large-scale production are the adherent nature of the HEK293T cell line and the cytotoxicity incurred by the VSV-G envelope. The adherent HEK293T cell line is traditionally 243 244 cultured in a T-flask, HyperFlask or multilayer cell factories [67,68]. Although these cell-culture methods 245 are sufficient for clinical-scale LV production, they are economically not viable for large-scale 246 production. To increase cell density for industrial LV production, fixed bed bioreactors, such as iCELLis Nano, iCELLis 500, and Scale-X Hydro, have been used [69,70]. The LV titer in TU using these 247 bioreactors is comparable to the current standard of LV production via adherent cells. Using adherent cell 248 249 lines for LV production can be costly due to the large amount of disposable materials required, such as flasks and medium. This issue has been circumvented by modifying or adapting variants of HEK293T to 250 251 suspension culture conditions [71-74]. Current LV production relies on transient transfection of three or 252 four plasmids to provide the building blocks the LV. The production of LV is a cellular process of shedding the viral vector into the media, which lasts only a few days. For large-scale LV production, this 253 classical production method is not cost-effective, due to the large amount of transfection reagents needed 254 and the exhaustion of the producer cells after one cycle of production [64]. Hence, establishing a 255 packaging cell line that expresses some or all of the plasmids of LVs would ease production and enables 256 257 the harvesting of several supernatants from a single production cycle [64]. However, the cytotoxic VSV-

G envelope does not allow its constitutive expression, and had hampered the establishment of stable packaging cell lines. Instead of using VSV-G, several groups have established a stable cell line with gamma retrovirus RD144 or MLV envelope to overcome the cytotoxicity of VSV-G [75-77]. These constitutive stable cell lines are capable of producing LV titer in the range of $1 - 5 \times 10^6$ TU/mL, and can continuously produce LVs for several months. As an alternative, an inducible packaging cell line expressing VSV-G has been developed, but these cell lines can only produce LVs for a few days [78].

264 LV supernatants contain contaminants, from the serum that is used for cell culture, the plasmid DNA for 265 transient transfection, and cell-derived proteins. Therefore, the downstream processing of LVs is required to further concentrate and purify the LV before clinical use. The major obstacle during the downstream 266 267 processing of LVs has been maintaining the bona fide conditions of the LV particles. The low stability of LV particles poses a tremendous challenge to the downstream processes, as LVs are sensitive to 268 environmental changes, such as temperature, pH, ionic strength, and shear stress due to the fragility of the 269 270 membrane envelope. The recovery of functional LV after purification is typically between 30 and 80%, 271 depending on the type of column and the pH and ionic strength of the buffers [79].

272 Large-scale production of LV has evolved significantly due to the increase in demand for LV-based products. However, the recovery yields are still far from meeting the current need. Improvements made to 273 the LV production pipeline, such as adaptation of the packaging cell line to suspension culture, can help 274 to increase productivity and reduce the overall production cost. However, much work still needs to be 275 276 done to achieve a continuous LV production process, otherwise hampered by the cytotoxicity of VSV-G. The downstream processing of LVs using current technological advances is challenging due to the 277 278 intrinsic fragility of LV. Further transition into a new LV production pipeline, e.g., suspension cells, can 279 overcome specific problems but will add on additional hurdles to the downstream processing of LVs [79].

280 3.5. APC targeting approaches

Recombinant viral vectors generally show broad specificity and transduce multiple cell types. In vaccine applications, DCs, with their unique ability to activate naïve T cells, are the ideal target for antigen delivery [80,81]. Taking into consideration the growing potential of LVs as a vehicle for T-cell eliciting vaccines, the development of LVs capable of transducing or redirecting expression in APCs *in vivo* could improve the safety and efficacy of LV vaccination. Here, we discuss the current advances in improving LV vaccinal vector targeting of APCs.

287 *3.5.1. Transductional targeting*

The pantropism of VSV-G-pseudotyped LVs results from the widespread expression of the VSV-G receptor, Low Density Lipoprotein (LDL) receptor, and the heparan sulfate proteoglycan attachment factor (Figure 3A) [21,82,83]. With the goal of minimizing off-target effects and improving safety, 291 multiple strategies based on alternative engineered glycoprotein have been described to redirect LV to 292 APC-specific cell surface receptors [80,81,84]. One strategy has been to use an ectopic hemagglutinin glycoprotein, such as Measles Virus Glycoprotein (MVG), which confers tropism towards cells 293 expressing CD46, Signaling Lymphocytic Activation Molecule (SLAM), and DC-SIGN (DC-Specific 294 Intercellular adhesion molecule-3-Grabbing Non-integrin). The SLAM receptor is constitutively 295 expressed on T and B cells, monocytes, and DCs, while DC-SIGN is specifically expressed on DC. 296 297 Therefore, MVG can be used to target LV towards DC (Figure 3B) [85,86]. The MVG-pseudotyped LV relies on fusion at the plasma membrane for cell entry rather than endocytosis, conferring an advantage 298 299 over VSV-G-pseudotyped LVs. However, a potential drawback of the use of MVG-pseudotyped LVs is 300 the pre-existing immunity against measles virus in the human populations [87].

301 Another strategy to direct LVs to APCs can be achieved via pseudotyping with Sindbis Virus envelope 302 Glycoprotein (SVG) following rational domain mutagenesis [88,89]. The standard laboratory-adapted 303 SVG confers tropism towards cells expressing heparan sulfate proteoglycan or DC-SIGN. Taking into 304 advantage the physical separation of the two receptor binding sites on SVG, selective mutations have been introduced to the heparan sulfate binding site, while leaving intact the DC-SIGN binding site. The 305 306 mutated SVG thus selectively binds to the DC surface protein via DC-SIGN but not to other cell types (Figure 3C). In vivo subcutaneous injection of LV pseudotyped with mutated SVG demonstrated 307 308 enhanced DC transduction, which was accompanied by the induction of strong antigen-specific immune 309 responses [88,89].

310 Chimeric envelope glycoproteins can also be modified to contain covalently-conjugated ligands or antibodies. This approach of using chimeric LV envelope glycoproteins has been used to couple MVG to 311 a single-chain antibody, scFv, specific to Major Histocompatibility Complex class II (MHC-II) α chain to 312 313 direct the LV and thus its transduction into DCs (Figure 3D) [81,90]. An LV pseudotyped with a fusion 314 of this scFv and MVG resulted in effective T-cell responses, albeit lower in magnitude and quality than those of VSV-G-pseudotyped LV. The reduced immunogenicity induced by LV pseudotyped with MVG-315 316 scFv fusion can be explained by the lower transduction efficiency and reduced stability of the vector [91]. The use of chimeric proteins has been shown to facilitate retargeting of the vector to specific moieties but 317 318 nonetheless, remains difficult, as such chimeric envelope glycoproteins often compromise the stability and immunogenicity of the vaccine vectors [92,93]. 319

An alternative strategy has been developed by using the nanobody display technology, for directing LVs towards APCs. Nanobodies, single monomeric variable antibody domains devoid of light chains, and similar to a conventional antibodies, are able to bind to specific antigens [94]. A nanobody specific to DC2.1 and DC1.8 surface DC receptors was incorporated, together with a fusogenic but binding-defective VSV-G, to the surface of LVs (Figure 3E). The resulting LV was thus specifically targeted to DCs to which it fused via the action of the mutated VSV-G. The use of such nanobody-engineered LVs demonstrated the feasibility of selective APC transduction and allowed the induction of an effective immune response, but again to a lesser extent than conventional VSV-G-pseudotyped LVs [84,85].

328 *3.5.2. Transcriptional targeting*

Another strategy for to program LVs for selective expression in APCs is via the insertion of tissue-329 specific promoters in the LV expression cassette. The most commonly used promoters in LVs are strong 330 and constitutive in nature and include CMV, Spleen Focus-Forming Virus (SFFV), and human Phospho-331 332 Glycerate Kinase (PGK) promoters [95]. The nonselective feature of these promoters has significant shortcomings, especially affecting the safety of the vectors. These promoters are more prone to 333 334 inactivation than cell-specific promoters, due to increased methylation at the CpG site of promoter enhancer sequences or viral LTR promoters [96]. They are also subjected to cytokine-induced 335 336 inactivation following a strong immune activation [97]. Therefore, restrictive promoters have been 337 explored to drive LV-mediated transgene expression in APCs.

An LV harboring the MHC-II-specific human HLA-DRa promoter induced restricted antigen expression 338 339 in MHC-II⁺ APCs, but failed to stimulate antigen-specific T-cell responses [35,98]. Indeed, immunization with this vector induced DC maturation, which led to down-regulation of the HLA-DRa promoter. Under 340 341 conditions, reduced antigen expression by mature DCs these and selective antigen 342 expression/presentation, primarily by immature DCs led to immune unresponsiveness and, seemingly, to T-cell anergy [35]. Another DC-specific promoter is the dectin-2 promoter, which is notably active in 343 cells of the myeloid lineage. Incorporation of the dectin-2 promoter in the LV successfully restricted the 344 345 transgene expression into APCs. An LV encoding for the melanoma antigen NY-ESO-1 under the 346 transcriptional regulation of the dectin-2 promoter induced robust antigen-specific T-cell responses [99].

347 We recently reported the use of a LV harboring the human β 2-microglobulin promoter, which contains highly conserved cis-regulatory elements, i.e., Interferon (IFN)-Stimulated Response Elements (ISREs), 348 and SXY modules [29]. ISREs are the binding site for the IFN family of regulatory factors, while SXY 349 350 modules interact with a multiprotein complex (Figure 4). These mediators transactivate the and are tightly 351 regulated by immune mediators, including cytokines, which are upregulated in immune cells [100,101]. 352 In addition, the human β 2-microglobulin promoter contains minimal proximal enhancers [29]. 353 Intramuscular immunization of mice with this LV led to highly efficient *in vivo* transgene expression by CD11b⁺ CD8⁻ myeloid, CD11b⁻ CD8⁺ lymphoid and plasmacytoid DC subsets. In this framework, the in 354 355 vivo transgene expression lasted at least seven days post-immunization and was accompanied by the induction of long-term memory CD8⁺ T-cell responses and complete efficacy in the immune eradication 356 357 of large solid tumors expressing the model antigen [29].

358 3.6. Mechanisms of T-cell induction by LVs

359 As mentioned above, LVs induces strong antigen-specific cytotoxic T-cell responses due to their marked ability to transduce DCs [25,26]. LVs can transduce murine plasmacytoid, myeloid, lymphoid, or bone-360 marrow-derived DCs and human plasmacytoid, myeloid, or monocyte-derived DCs [26,102,103]. In 361 humans, the plasmacytoid DC subset is the least and the monocyte-derived DC the most susceptible to 362 LV transduction. However, the permissiveness of monocyte-derived DCs to LVs decreases as they 363 differentiate [104]. The mechanism underlying the strong induction of the cytotoxic T-cell response 364 induction by LV immunization is yet to be unraveled. As LVs are RNA viral vectors, much attention has 365 been focused on possible innate single-stranded RNA sensing mechanisms in DCs following their 366 367 interaction with LVs. The LV RNA genome was reported to stimulate intracellular innate pathways via 368 the Toll-Like Receptor (TLR) 7 in human plasmacytoid DCs, resulting in the production of IFN-I and 369 TNF- α , which in turn activated by stander myeloid DCs [104,105]. However, the impact on the induction of the T-cell response was not assessed in these studies. In mice, myeloid DCs produce IFN-I and TNF-α 370 following interaction with LVs and through TLR3 and TLR7 signaling. In this study, mice deficient for 371 TLR3 and TLR7 signaling showed weaker T-cell responses than their wild-type counterparts [102]. TLR7 372 373 is probably not the only pathway to trigger IFN-I production, because a TLR7 antagonist was not 374 sufficient to prevent IFN-I induction upon LV transduction, suggesting the presence of alternative 375 pathways. However, it was shown that IFN-I was not critical for LV-mediated T-cell activation, which 376 was further confirmed by the use of IFNAR KO mice [63,103]. Recently, we also demonstrated that 377 conditional deletion of IFNAR in CD11c⁺ cells in vivo does not affect the induction of the T-cell response LVs (our unpublished data). 378

379 Conversely, a deficiency of IFN-I was demonstrated to increase the transduction efficiency of LVs in the liver, therefore increasing the gene expression for a longer duration [103]. This ability to mediate long-380 381 term gene transfer is critical in the context of gene therapy but not vaccination. One explanation is that in 382 the context of vaccination, a transient but adequate transgene expression is sufficient for the induction of 383 a high-quality T-cell response. In this context, it is still a challenge to determine the level and duration of transgene expression needed for a high-quality T-cell response in LV immunization, as the concept of 384 "one size fits all" transgene expression may not be applicable in T-cell induction due to differences in the 385 nature of the epitopes. Another study aiming to decipher the mechanism of immune induction by LVs 386 387 showed that only conventional DCs but not plasmacytoid DCs, were required for T-cell induction in a murine model, and that the CD8⁺-T cell induction was independent of the TLRs, Myeloid differentiation 388 389 primary response 88 (MyD88) adaptor, Interferon Regulatory Factor (IRF), Retinoic acid Induced Gene I 390 (RIG-I), and Stimulator of Interferon Genes (STING) signaling pathways. Only the blockade of the central NF- κ B signaling pathway in CD11c⁺ DCs inhibited the CTL induction [63]. In summary, these 391 results should be evaluated with care, as LV production in the laboratory setting is often prone to 392 contamination from producer cells and DNA/RNA, resulting in activation of the innate sensing pathways 393

In addition, the experimental conditions such as different multiplicities of infection, LV
 preparations, doses, and immunization routes can also lead to different outcomes in T-cell induction.

396 3.7. Comparison of LVs to adenoviral vectors

397 Adenoviruses are non-enveloped icosahedral viruses that contain a linear double-stranded DNA genome. There are 57 various serotypes of human adenoviruses, classified into species A to G with distinct 398 399 tropism and receptors to target host cells. Human adenovirus subgroup C, and in particular Ad5, is by far the best characterized and widely used vector for clinical applications. Adenoviral vectors, and notably 400 401 Ad5, are still very attractive vectors for gene delivery applications for several reasons. They (i) infect a variety of dividing and quiescent cells, with their main tropism directed to epithelial cells, fibroblasts, 402 403 hepatocytes and endothelial cells, (ii) exhibit a minimal risk of insertional mutagenesis, as the genome of Ad5 remains as episomal elements after entering the host cell nucleus, (iii) are highly stable and can be 404 405 produced at very high titers, due to their non-enveloped nature, (iv) are replication-defective, and (v) 406 accept large DNA payloads of up to 35 kb [107]. Despite these advantages, Ad5 poorly infects certain cell types and tissues, including brain tissue, skeletal muscles, hematopoietic cells and DCs, which are 407 important targets for gene therapy and vaccination [108]. However, the viral tropism of adenoviral 408 409 vectors can be modified to target other cell types or tissues by incorporating peptide ligands within their surface protein or by pseudotyping with surface proteins of non-human adenovirus species [109]. 410

411 The major drawback of adenoviral vaccination vectors is the pre-existing anti-adenoviral immunity in the 412 human populations. More than 80 % of the human population has been pre-exposed to at least one 413 serotype of human adenoviruses and has developed adenoviral serotype-specific immunity. Adenoviral-414 specific neutralizing antibodies are directed against the capsid and hexon proteins of the viral structure. In addition, both CD4⁺ and CD8⁺ T cells specific to adenoviruses are found in pre-exposed individuals. 415 416 Such pre-existing humoral immunity interferes with uptake of the adenoviral vector, while the preexisting cell-mediated immunity can dampen the efficacy of adenoviral-mediated gene transfer, thus 417 shortening the duration of transgene expression [22,107]. Ad5-specific antibodies can opsonize the 418 419 vector, inducing uptake of these complexes via Fc receptors by macrophages, DCs, and neutrophils, which results in rapid vector clearance and decreased tissue transduction, triggering intense inflammatory 420 responses [110,111]. Even in individuals without pre-existing adenoviral immunity, the first 421 administration of adenoviral vectors induces specific humoral and cellular immune responses. The 422 423 repeated administration of the same vector for prime-boost or distinct vaccination purposes leads to the 424 same issues as for pre-existing natural immunity. To circumvent the problem of pre-existing adenoviral immunity in humans, chimpanzee adenovirus-based vectors have been developed [112]. In addition to 425 their property of being culturable in human cell lines, they also have a low seroprevalence in the human 426 427 populations, hence significantly decreasing the effect of pre-existing immunity. Although serum neutralizing antibodies against chimpanzee adenoviruses are detectable in only 0 to 4% of human
populations in Europe and the United States, the prevalence can be significant, i.e., up to 20% in human
populations in developing countries, including sub-Saharan Africa [112].

The Ad5 vector is highly inflammatory and can trigger a series of innate immune signaling pathways that 431 result in substantial secretion of proinflammatory cytokines, such as IL-1 β , IL-6, IL-12, IFN- γ , and TNF-432 433 α [22]. Ad5 vectors bind to complement proteins C4 and C4-binding protein and activate the complement 434 system, platelet aggregation, and the secretion of inflammatory cytokines [113,114]. The Ad5 capsid interacts with TLR2, and the Ad5 DNA is sensed by TLR9, which activates the NFkB and IRFs 435 436 pathways, resulting in the production of numerous pro-inflammatory cytokines and chemokines [115]. 437 Ad5 double stranded DNA also activates the inflammasome [116]. Such induction of proinflammatory cytokines after Ad5 administration leads to a robust humoral and cellular immune response, but can 438 439 sometimes also cause drastic adverse effects. A study aimed to evaluate the toxicity of systemic high-dose Ad5 administration showed the response to be lethal when 2×10^{11} active viral particles (vp) were 440 administrated intravenously to mice with pre-existing Ad5 immunity established by previous 441 intramuscular injection [117]. Similarly, high doses of Ad5 (i.e., $> 10^{13}$ vp per kg), are also lethal for 442 larger animals [22]. Intravenous administration of a high dose of Ad5, i.e., 6×10^{11} vp/kg, caused death in 443 444 a volunteer participant during a phase I gene therapy clinical trial, due to the triggering of a massive immune response and multiorgan failures as a result of high-dose administration and pre-existing 445 446 immunity. Importantly, the activation of innate immunity by adenoviral vectors is independent of the 447 transduction because inactive vector particles also interact with the receptors of the innate immunity 448 [110]. Due to the need for repeated vector administration for gene therapy, the use of the old generation 449 of Ad5 in gene therapy is facing a sharp decline due to serious adverse effects, such as cellular toxicity 450 and organ failure, observed in multiple clinical trials [22]. These safety concerns have been studied extensively and addressed by the development of a new generation of adenoviral vectors that are less 451 452 toxic and immunogenic [22].

Adenoviral vectors have been explored for use in vaccination due to their ability to induce a robust 453 454 immune response. These vectors have reached the clinical stage and have shown promising results in the induction of antibody and CD8⁺ T-cell responses to resolve infections with viruses, other intracellular 455 pathogens and cancer cells. During the Ebola outbreak, three adenoviral-based vaccine approaches were 456 457 explored: (i) the chimpanzee adenovirus type 3 encoding the Ebola virus glycoprotein (ChAd3-ZEBOV1) 458 from GlaxoSmithKline, (ii) a prime-boost regimen combining human adenovirus type 26 (Ad26-ZEBOV) 459 and an MVA vector encoding the vector EBOV, Sudan virus, and Marburg virus glycoproteins and Tai 460 Forest virus nucleoprotein (MVA-BN-Filo2) from Johnson & Johnson, and (iii) Ad5 expressing the Ebola virus makona variant glycoprotein from the Chinese Federal Agency (FDA). These vaccines were 461 462 developed in a short time and progressed rapidly into phase I clinical trials [118]. Among them, Ad26463 ZEBOV/MVA-BN-Filo2 showed the presence of EBOV glycoprotein-specific IgG in 80 % of the 464 participants with limited adverse events. Hence, this candidate vaccine further progressed into phase II and III clinical trials (NCT04028349) [119]. On the other hand, the Ad5-based Ebola vaccine from the 465 Chinese FDA showed poor efficacy in the phase I clinical trial, especially in individuals with pre-existing 466 adenoviral immunity, adding further credence to the issue of pre-existing adenoviral immunity in 467 vaccination [118]. During the COVID-19 pandemic, human Ad26- and/or Ad5-based vaccines (Sputnik-468 V and Ad26.COV2.S, Johnson & Johnson) and the simian ChAdOx1 nCoV-19 vaccine (AZD1222) were 469 also among the very first viral vectors approved for vaccine use [120]. Both Ad26 and ChAdOx1 were 470 471 well tolerated and most subjects receiving these vaccines experienced mild to moderate side effects, such 472 as pain at the injection site, headache, fatigue and muscle pain. For both vaccines, the reactogenicity was 473 higher in groups receiving a higher dose of vaccine, but a decrease in reactogenicity was observed with 474 increasing age [121,122]. Following administration of Ad26 or ChAdOx1 to the public, rare cases of thrombocytopenia were reported but the exact correlation between the adenoviral vector vaccination and 475 476 the incidence of thrombocytopenia is still uncertain [123]. Most adenoviral vector-based vaccines have demonstrated good immunogenicity and safety, but a small number of the trials have indicated certain 477 478 serious adverse effects when using these vectors. One of the examples of such a trial is the first cellular 479 prophylactic Ad5 vaccine trial against HIV. This trial was suspended due to unexpected enhancement of 480 HIV infection in vaccinated volunteers [124]. Activation of the DC-T cell axis by Ad5 immune 481 complexes appears to have been responsible for the increased incidence of HIV acquisition among 482 vaccinated individuals, indicating a serious side effect of the highly inflammatory Ad5 when used in HIV patients [125]. Asides from HIV, Ad5 vectors have also been developed against many other pathogens, 483 484 such as Zika Virus (ZIKV), Influenza virus, Mycobacterium tuberculosis, plasmodia, and SARS-CoV-2, 485 and have demonstrated strong immunogenicity against these diseases [118,126].

486 Adenoviral vectors are easy to design and can be rapidly produced in mass quantity. The ease of mass 487 production is of supreme importance during an emergency outbreak to supply the demand within a short 488 period of time, as demonstrated by adenoviral vectors during the COVID-19 pandemic. In contrast to Ad, 489 the high cost and difficulties in mass production of LVs impede the worldwide implementation of LV 490 vaccines. However, the extensive improvements in industrial-scale LV production have further advanced the approval of LV-based therapies in clinical trials and for human use. The large payload capacity of 491 492 adenoviral vectors relative to LVs is another advantage. Adenoviral vectors can accommodate large 493 foreign genes of up to 35 kb, otherwise difficult for viral vectors with smaller payload capacities. In 494 contrast to adenoviral vectors, LVs only minimally induce only minute levels of phenotypic and 495 functional DC maturation in vitro and in vivo [63,127] (our unpublished data) in murine models, indicative of their negligible pro-inflammatory properties. The LV immunization doses in non-human 496 primates and humans are from 10^6 to 10^8 TU, which are significantly lesser than the above-mentioned 497

498 doses used for adenoviral vectors [15]. LVs are also suitable for repeated administration in gene therapy 499 and vaccination due to the ease of pseudotyping with heterologous VSV-G and their weak inflammatory property. The safety profile of LVs, despite not being as widely studied as adenoviral vectors, has so far 500 501 been shown to be excellent in vaccinated animals and humans with priming and boosting [128]. On the other hand, the safety profile of adenoviral vectors in terms of inflammation, toxicity, and pre-existing 502 immunity in humans is likely to be continuously be improved. The favorable scientific and practical 503 504 features of both vectors clearly show their ability to address many diseases. However, each vector has its own shortcomings that need to be addressed to unlock their potential of these viral vectors for 505 506 vaccination.

507 3.8. LV-based vaccination in preclinical models

508 The field of LV-based vaccination is still in its infancy compared to LV-based gene therapy. One of the 509 reasons that LVs have come to the fore in vaccination in recent years is their ability to transduce DCs. 510 Multiple LV vaccine candidates are being tested for tumor immunotherapy and a small handful are being tested for prophylactic T-cell immunity against infectious diseases [15,129,130]. Most attention on LV-511 based prophylactic T-cell immunity has focused on its use to target HIV. Numerous preclinical studies in 512 animal models have shown great success in strongly eliciting HIV-specific antibodies and cytotoxic CD8⁺ 513 T cells. A prime-boost regimen of ILVs encoding SIV macaque 239 Gag (SIVmac239 Gag) efficiently 514 515 protected Cynomolgus macaques when they were challenged with SIVmac251. This protection was 516 accompanied by a reduction in the viral load of two orders of magnitude and full preservation of CD28⁺ CD95⁺ memory CD4⁺ T cells during the primo-infection [15]. Another study that used a SIV-based NILV 517 encoding EnvC.1086 gp140 showed durable antibody and T-cell responses after one year of a single 518 immunization in rhesus macaques, with most of the vaccine-induced T cells being polyfunctional CD4⁺ 519 520 central memory cells [131]. Therapeutic vaccination of macaques, chronically infected with Simian Human Immunodeficiency Virus (SHIV), with a NILV encoding the SIV gag, induced durable T-cell 521 522 responses, leading to sustainable virus control for more than 20 weeks [59]. Overall, these data suggest a 523 durable and protective immune response following LV vaccination, in particular for complex diseases 524 such as HIV, further demonstrating the potential of LV-based vaccines to advance to human clinical trials. An LV-based DC vaccine has been developed in which HIV-1 or LCMV antigens are co-expressed 525 526 with CD40 ligand (CD40L) and possibly with a soluble Programmed cell Death 1 (PD-1) dimer. This vector activates DCs via CD40 and blocks the checkpoint PD Ligand 1 (PD-L1). Injection of appropriate 527 528 mice with DCs transduced with such LV-based DC vaccines have shown induction of T-cell effector and 529 memory cells and marked degrees of anti-viral protection [91,132,133].

Notably, LVs have also demonstrated superior immunogenicity relative to other vaccine platforms, such
as those based on DNA, protein, and Ad5 [58,134,135]. The absence of any adverse effects of LVs was

also established in humans in a phase I HIV therapeutic clinical trial [136]. Although LV-based vaccine candidates are at their early stage of clinical development, increasing evidence of their efficacy and safety reinforce the potential and interest of these vectors in vaccination. LV vaccinations against malignancy and infectious diseases have consistently demonstrated the induction of strong humoral and cellular immune responses, accompanied by highly significant protection in preclinical animal models (Table 1).

537 Our recent work on anti-flaviviral immunity, notably with ZIKV, illustrates the anti-viral efficacy of LVbased vaccination. ZIKV caused an unprecedented global health crisis in 2016 due to its potential to 538 induce neurological defects in the developing fetus. As part of the concerted effort to combat ZIKV 539 540 infection, we developed a NILV-based vaccine candidate encoding the ZIKV pre-membrane (prM) and 541 envelope glycoprotein (E). A single systemic immunization of: (i) IFN α/β receptor knockout A129 mice, particularly susceptible to Zika, or (ii) immunocompetent mice, induced strong serum neutralizing 542 543 antibody titers, which correlated with full and long-term protection, measurable as early as seven days up 544 to the last time point studied, i.e. six months post-vaccination [135].

545 More recently, we developed a NILV-based vaccine candidate against COVID-19, that encodes for the full-length Spike glycoprotein of SARS-CoV-2 (S_{CoV-2}) and elicits high titers of neutralizing antibodies, 546 as well as strong and poly-specific CD8⁺ T-cell immunity [55]. Due to the non-replicative, non-547 integrating, non-cytopathic, negligibly inflammatory features of NILV, it was possible to use this vaccine 548 549 candidate for intranasal administration. By inducing mucosal immunity, and notably the production of 550 lung IgG, IgA, and CD8⁺ T cells, and targeting the immune responses to the respiratory tract, at the entry site of the virus, it was possible to achieve full protection, characterized by the absence of detectable 551 replicating virus, and the inhibition of deleterious inflammation and tissue injury in the lung [55]. This 552 553 was demonstrated in mice, in which the expression of the SARS-CoV-2 receptor human Angiotensin 554 Converting Enzyme 2 (hACE2) was induced by in vivo transduction of respiratory tract cells by an adenoviral vector, and in the highly susceptible golden hamsters, which are naturally permissive to 555 556 SARS-CoV-2 replication, mimicking the human COVID-19 physiopathology. We also developed a hACE2 transgenic mouse model with unprecedented brain permissiveness to SARS-CoV-2 replication 557 558 leading to a lethal disease in <4 days post infection. We used this highly stringent transgenic model to provide the proof of principle that an intranasal booster immunization with the NILV:: S_{CoV-2} vaccine 559 560 candidate achieves full protection of both respiratory tract and brain against SARS-CoV-2 [137]. Given the neurotropism of SARS-CoV-2, the COVID-19-associated symptoms such as headache, anosmia, 561 562 dysgeusia, impaired consciousness and cerebrovascular disease, the presence of SARS-CoV-2 in the 563 nasopharynx and brain, and viral entry into the brain via the olfactory mucosa, the feasibility of nasal vaccination by NILV merits consideration for vaccine development [54,138-141]. Other vaccine 564 strategies currently being developed do not take into account the protection of the central nervous system. 565

Aside from the prophylactic vaccination against infectious diseases, we also recently evaluated the oncoimmunotherapeutic impact of LV::OVA using the EG.7 tumor cell line expressing the surrogate OVA antigen [29]. A single intramuscular administration of LV::OVA to mice bearing large subcutaneous tumors, i.e., with an average volume of ~250 ^{mm3}, led to complete tumor eradication and a high survival rate of 83%. Only 50% of their Ad5::OVA-vaccinated counterparts were protected in the same experiment. Therefore, LV onco-therapy provided higher protection and better survival than Ad5 in this murine immune-therapeutic setting [29].

573 4. Conclusion/Discussion

LVs are potentially powerful vaccine vectors by virtue of their efficiency in transducing DCs in vivo and 574 in inducing both strong and long lasting humoral and T-cell responses and effective protections in 575 576 multiple preclinical models of infection and oncology. In addition to their high immunogenicity, 577 integrase-deficient NILVs present a notable safety profile. These vectors are negligibly pro-inflammatory 578 and non-replicative. Here, we reviewed the literature relating to the virological and immunological aspects of these vectors and provided elements of comparison with the more widely used, gold standard 579 adenoviral vectors. We stress the quasi-absence of pre-existing immunity against LVs pseudotyped by the 580 envelope glycoprotein of VSV, to which human populations have only been very rarely exposed, unlike 581 adenoviral-based vectors, against which more than 80% of humans may have immunity, with the 582 583 limitations that the pre-existing humoral and T-cell responses can have on the efficacy and safety of these 584 vectors. The very weak inflammatory properties of LVs, as well as their non-cytopathic nature, pave the 585 way for their use in mucosal vaccination, with particular interest in infectious diseases that affect the respiratory tract or brain. Recent results in various preclinical models reinforce the interest of these 586 587 vectors in the prevention of infectious diseases and in onco-immunotherapy.

588 **5. Expert Opinion**

589 LVs have emerged as a powerful platform for gene therapy and vaccination purposes, and exhibit several 590 advantages over other viral vectors. Considering the traits of LVs detailed in this review, LVs offers a 591 promising opportunity for further vaccine development, suitable for a large number of clinical applications. To date, no adverse effect has been observed in preclinical animal models in diverse settings 592 593 or in a clinical trial with LVs against HIV-1. Furthermore, our reported COVID-19 LV-based vaccine candidate is in progress to proceed to clinical trials. Thus far, a major limitation of the use of LVs in 594 595 vaccination has been linked to constraints in technology transfer to manufacturers for their production in 596 large quantities while maintaining an acceptable production yield. Thus, industrial-scale production for 597 mass vaccination is still nascent. However, it must be taken into account that, compared to the adenoviral 598 vaccine vectors that are currently mass produced, and which are injected at doses on the order of 5- 15×10^{10} vp per individual in humans, while ILV-based vaccination only requires the administration of 599

 $5-500 \times 10^6$ TU per individual for human use [126,128,142]. Therefore, the much lower effective doses of LVs should will compensate for their high production cost. LVs have largely shown their effectiveness, including the mucosal and, in particular, intranasal — vaccination route. With the first Good Manufacturing Practice (GMP) grade batches, the completion of toxicology studies adapted to the nasal administration route, will be required before LV can enter the clinic for mucosal immunization.

A promising area to further optimize the immunogenicity of LVs will be to engineer LVs to: (i) route 605 606 antigens to the MHC-II presentation machinery for CD4⁺ T-cell induction, (ii) co-encode antigens and cytokines/chemo-attractants, and (iii) co-encodes antigens and elements for targeting them to relevant DC 607 subtypes. Additional applied research also needs to be conducted to assess the effectiveness of LVs in the 608 prevention and/or therapy of chronic infectious diseases, such as malaria and tuberculosis, as well as 609 cancers. In the cancer field, the use of preclinical models, other than subcutaneous solid tumors, for 610 611 example models of tumor dissemination will be essential. A head-to-head comparison of LV- and RNA-612 based vaccines in terms of antibody affinity, T-cell responses, pathogen neutralizing potential, immune 613 memory characteristics, and the duration of the protective immunity, as well as side effects, will be valuable. 614

LVs meet all the criteria for efficacy, as they trigger the various arms of adaptive immunity, with a high 615 protective potential, without any side effects linked to innate immune reactions, as tested in numerous 616 preclinical models by independent expert groups in the field, and pre-existing vector-specific immunity is 617 618 absent in human populations. Overall, we believe that LVs have the potential to offer prophylactic and 619 therapeutic effects against infectious diseases and cancer. In the near future, following their validation in regulatory preclinical trials, LVs have a realistic potential to be implemented in clinical practice, with 620 significant use in vaccination. The next boost for LV-based vaccines will rely on niche technologies that 621 622 will enable affordable large-scale production of LV doses, bringing us one step closer to the mass use of LVs in vaccination. 623

624

625 Legend to the Figures

Figure Erreur ! Il n'y a pas de texte répondant à ce style dans ce document.. Schematic representation of HIV-1 genome and development of LV system.

628 (A) The essential (gag, pol and env), accessory (vif, vpr, vpu and nef) and regulatory (tat and rev) genes 629 of HIV-1 are flanked by two identical long terminal repeats (LTRs). Ψ represents the packaging signal, 630 while the central polypurine tract (cPPT) and central termination sequence (CTS) were represented as black line. The cPPT and CTS forms a triple helical DNA flap, ensuring proper nuclear translocation of 631 the pre-integration complex. RRE, represented in yellow circle, is the rev response element, responsible 632 633 for transporting the unspliced RNA into cytoplasm. (B) Production of recombinant LV is separated into 3 distinct plasmid constructs. The expression cassette of LV contains cis-acting sequences (Ψ , RRE and 634 635 cPPT/CTS) and gene of interest under the control of an internal promoter which are flanked by two LTRs. The packaging plasmid encodes for gag, pol, tat and rev while the envelope plasmid encodes for the 636 637 envelope protein, both plasmid expression under the transcriptional control of P_{CMV}. LTR, long terminal repeats; Ψ, packaging signal; RRE, rev response element; cPPT, central polypurine tract; CTS, central 638 termination sequence; P_{CMV} cytomegalovirus promoter. 639

640 Figure 2. Reverse transcription of self-inactivated (SIN) vector.

Reverse transcription is initiated when minus strand DNA synthesis starts from the primer binding site 641 642 (PBS) of the single stranded viral RNA (shown in red line), copying the U5 and R region of the 5' genome. The RNaseH of the reverse transcription enzyme degrades the viral RNA that has been copied 643 (shown as red dotted line). The minus strand DNA translocated to the 3' end of the viral genome using 644 645 the R sequence, and continue to elongate to form a full length minus strand DNA, which now contains the 646 $\Delta U3$ (shown as blue line). The remaining viral RNA is degraded by the RNaseH activity, except for central polypurine tract (cPPT) and PPT, which are resistant to degradation. The cPPT and PPT are used 647 648 as primers for second strand plus DNA synthesis (shown as black line). After a second strand transfer, 649 DNA synthesis continues to the cPPT, displacing ~100 nucleotides of cPPT-primed DNA and terminates 650 at the central termination sequence (CTS), generating a kink within the three stranded DNA structure 651 called the DNA flap [143]. At this point, the reverse transcription is completed and both plus and minus strand of DNAs contain both copies of LTRs that have identical $\Delta U3$ at both ends. 652

653 Figure 3. Strategies for redirecting LV vectors to APC via engineered glycoproteins.

(A) VSV-G-pseudotyped LVs can infect a wide range of cell types via binding to LDLR receptor and 654 655 heparan sulfate which are found in all cell types. (B) Measles virus glycoprotein (MVG)-pseudotyped LV infect APC preferentially via recognition of DC-SIGN or signaling lymphocytic activation molecule 656 (SLAM) expressed on APC, and mediate entry into cells via direct membrane fusion. (C) The mutated 657 658 sindbis virus envelope glycoprotein (muSVG)-pseudotyped LV confer tropism towards DC via binding to DC-SIGN. (D) LV pseudotyped with MVG-MHC II-specific single-chain antibody (scFv) recognizes 659 MHC II-expressing APC. (E) LV pseudotyped with VSV-G-fusion DC2.1 or DC1/8-specific nanobody 660 661 transduced only DC.

662

Figure 4. Schematic representation of LV vector containing β2m internal promoter.

LTR: Long Terminal Repeats; SD, Shine-Dalgarno sequence; RRE, Rev Response Element; cPPT,
central PolyPurine Tract; CTS, Central Termination Sequence; ISRE, IFN-Stimulated Response Element;
WPRE, Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element.

667 Table 1. LV-based vaccines against malignancies and infectious diseases.

Disease	Vector Type*	Antigen(s)	Characteristics of the immune response	Reference
	ILV	Melan-A	CD8 ⁺ and CD4 ⁺ responses against Melan-A	[144]
	ILV	New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)	CD8 ⁺ response against NY- ESO-1	[145]
	ILV	Hsp70 co-expressed Tyrosine related protein 2 (TRP2)	CD8 ⁺ response against TRP2	[146]
Melanoma	ILV	Melan-A	CD8 ⁺ response against Melan-A	[147]
	ILV	MHC II promoter driving TRP2 expression	CD8 ⁺ response against TRP2	[35]
	ILV	NY-ESO-1	CD8 ⁺ , CD4 ⁺ and antibody response against NY-ESO-1	[148]
	ILV	DC-specific promoter driving expression of NY-ESO-1	CD8 ⁺ and CD4 ⁺ response against NY-ESO-1	[99]
	ILV	Tyrosine related protein 1 (TRP1)	CD8 ⁺ response against TRP1	[149]
	ILV	Human telomerase reverse transcriptase (hTERT)	CD8 ⁺ response against hTERT	[150]
	NILV pseudotyped with a modified Sindbis virus envelop protein	Melanoma antigen gp100	CD8 ⁺ response against gp100	[89]
	NILV pseudotyped with a modified Sindbis virus envelop protein	NY-ESO-1 [#]	CD8 ⁺ and CD4 ⁺ response against NY-ESO-1	[151] [152] [153]
	NILV	Tyrosine related protein 2 (TRP2)	T cells against TRP2	[154]
Prostate Cancer	ILV	Prostate stem cell antigen (PSCA)	CD8 ⁺ and CD4 ⁺ response against PSCA	[155]
Hepatitis B virus (HBV)	NILV	secreted HBsAg	Antibody and T cells against HBsAg	[34]
Hepatitis cytomegalov irus	NILV	Prime with Ad5 harboring envelope 1 (E1) and envelope 2 (E2) glycoproteins, boosted with NILV pseudotype with E1 and E2, harboring the non- structural protein 3 (NSP3)	Broadly neutralizing antibodies against E1, E2 and NS3	[156]
Human Papilloma Virus	NILV	E7 fused to calreticulin to enhance MHC I presentation	CD8 ⁺ and antibody response against E7	[157]
Malaria	NILV	Plasmodium yoelii Circumsporozoite Protein (Py CSP)	CD8 ⁺ response against CSP	[17]
West Nile Virus	ILV	secreted soluble form of the envelope E-glycoprotein (sE)	Antibody against sE	[19]
	NILV	secreted soluble form of the envelope E-glycoprotein (sE)	Antibody against sE	[17] [24]
Influenza	NILV	hemagglutinin (HA) and nucleoprotein (NP)	CD8 ⁺ response against NP; Antibodies against HA and NP	[18]
Zika	ILV and NILV	pre-membrane envelope (prM-E)	Antibody against prM-E	[135]
SARS-CoV-	ILV and NILV	Full length Spike protein	Antibody and CD8 ⁺ T cells against Spike	[55,137]
2				

		multiple encoded HIV	
		epitopes CD8 ⁺ T cell response and	
NILV	Codon-optimized gp120	antibody response against gp120	[158]
ILV	Codon-optimized SIV gp120	CD8 ⁺ and CD4 ⁺ responses	[16]
ILV	HIV Gag, Pol and Rev	CD4 ⁺ and CD8 ⁺ T cell response against Gag, Pol and Rev	[159]
SIV-based NILV	1086 gp140 and 1176 gp140	Antibodies against 1086 and 1176 gp140	[30]
SIV-based NILV	HIV-1 EnvC.1086 gp140	Antibodies, CD8 ⁺ and CD4 ⁺ against gp120	[131]
SIV-based NILV	HIV-1 EnvC.CH505 gp140	Antibodies and T cells against gp140	[58]
SIV- and HIV- based NILV	SIV-gag and (bnAb) PGT121	$CD4^+$ and $CD8^+$ against SIV gag	[59]
ILV [#]	HIV Gag, Pol, Nef	$\mathrm{CD4}^{\scriptscriptstyle +}$ and $\mathrm{CD8}^{\scriptscriptstyle +}$ T cells	[128]

*Unless otherwise stated, all ILV and NILV vectors stated here are HIV-1 based vector pseudotyped with VSV.G. #Used in clinical trial 669 670

671 Acknowledgement

The authors are very grateful to Dr. François Anna (Pasteur-TheraVectys Joint Laboratory) for helpfuldiscussions.

674

675 **Funding**

- 676 This manuscript was funded by TheraVectys and Institut Pasteur.
- 677

678 **Declaration of Interests**

Min-Wen Ku is an employee of TheraVectys, Pierre Charneau is the founder and CSO of TheraVectys,
Laleh Majlessi has no relevant affiliations or financial involvement with any organization or entity with a
financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants
or patents received or pending, or royalties.

684

685 Author contribution

All authors substantially contributed to the conception and design of the review article and interpreting
the relevant literature, and have been involved in writing the review article or revised it for intellectual
content.

689

690 **References**

- Detmer A, Glenting J. Live bacterial vaccines--a review and identification of potential hazards.
 Microb Cell Fact, 5, 23 (2006).
- 693 2. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies.
 694 *Braz J Med Biol Res*, 45(12), 1102-1111 (2012).
- 695 3. Ura T, Okuda K, Shimada M. Developments in Viral Vector-Based Vaccines. *Vaccines (Basel)*,
 696 2(3), 624-641 (2014).
- 697 4. Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. *Nat Rev Microbiol*, 12(11), 765-771
 698 (2014).
- 699 5. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines.
 700 *Biotechnology*, 20, 363-390 (1992).
- 6. Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. *Expert Rev Vaccines*, 3(4 Suppl),
 S89-97 (2004).
- 703 7. Moss B, Smith GL, Mackett M. Use of vaccinia virus as an infectious molecular cloning and
 704 expression vector. *Gene Amplif Anal*, 3, 201-213 (1983).
- 8. Wen AM, Steinmetz NF. Design of virus-based nanomaterials for medicine, biotechnology, and
 energy. *Chem Soc Rev*, 45(15), 4074-4126 (2016).
- 707 9. Cooney EL, Collier AC, Greenberg PD *et al.* Safety of and immunological response to a
 708 recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. *Lancet*, 337(8741),
 709 567-572 (1991).
- 10. Long SS, Prober CG, Fischer M. Principles and practice of pediatric infectious diseases. Elsevier
 (2018).
- Casimiro DR, Chen L, Fu TM *et al.* Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol*, 77(11), 6305-6313 (2003).
- 715 12. Zhu FC, Guan XH, Li YH *et al.* Immunogenicity and safety of a recombinant adenovirus type-5716 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind,
 717 placebo-controlled, phase 2 trial. *Lancet*, 396(10249), 479-488 (2020).
- Dicks MD, Guzman E, Spencer AJ *et al.* The relative magnitude of transgene-specific adaptive
 immune responses induced by human and chimpanzee adenovirus vectors differs between
 laboratory animals and a target species. *Vaccine*, 33(9), 1121-1128 (2015).
- 14. Dicks MD, Spencer AJ, Coughlan L *et al.* Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. *Sci Rep*, 5, 16756 (2015).
- Beignon AS, Mollier K, Liard C *et al.* Lentiviral vector-based prime/boost vaccination against
 AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge
 in macaques. *J Virol*, 83(21), 10963-10974 (2009).

** A prime-boost LV-based vaccine encoding the SIV GAG antigen confers strong reduction in viremia
 level (~2 log₁₀) in a model SIVmac251 infection of cynomolgus macaques.

- Buffa V, Negri DR, Leone P *et al.* Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. *Viral Immunol*, 19(4), 690-701 (2006).
- 732 17. Coutant F, Sanchez David RY, Felix T *et al.* A nonintegrative lentiviral vector-based vaccine
 733 provides long-term sterile protection against malaria. *PLoS One*, 7(11), e48644 (2012).
- 18. Gallinaro A, Borghi M, Bona R *et al.* Integrase Defective Lentiviral Vector as a Vaccine Platform
 for Delivering Influenza Antigens. *Front Immunol*, 9, 171 (2018).
- Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, Charneau P. A single immunization
 with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective
 humoral immunity against West Nile virus. *J Gene Med*, 8(3), 265-274 (2006).
- Abordo-Adesida E, Follenzi A, Barcia C *et al.* Stability of lentiviral vector-mediated transgene
 expression in the brain in the presence of systemic antivector immune responses. *Hum Gene Ther*,
 16(6), 741-751 (2005).

- 742 21. Hastie E, Cataldi M, Marriott I, Grdzelishvili VZ. Understanding and altering cell tropism of vesicular stomatitis virus. *Virus Res*, 176(1-2), 16-32 (2013).
- Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.
 Curr Gene Ther, 13(6), 421-433 (2013).
- 746 23. <u>https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics.</u>).
- Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. *PLoS One*, 3(12), e3973 (2008).
- Esslinger C, Romero P, MacDonald HR. Efficient transduction of dendritic cells and induction of
 a T-cell response by third-generation lentivectors. *Hum Gene Ther*, 13(9), 1091-1100 (2002).
- He Y, Zhang J, Mi Z, Robbins P, Falo LD, Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J *Immunol*, 174(6), 3808-3817 (2005).
- Zhan Y, Chow KV, Soo P *et al.* Plasmacytoid dendritic cells are short-lived: reappraising the
 influence of migration, genetic factors and activation on estimation of lifespan. *Sci Rep*, 6, 25060
 (2016).
- Wang XY, Zhang JH, Zhang X, Sun QL, Zhao CP, Wang TY. Impact of Different Promoters on
 Episomal Vectors Harbouring Characteristic Motifs of Matrix Attachment Regions. *Sci Rep*, 6,
 26446 (2016).
- Ku MW, Authié P, Nevo F *et al.* Lentiviral Vector induces high-quality Memory T Cells via
 Dendritic Cells transduction. *Comm. Biol.*, 4(1), 713 (2021).
- 30. Blasi M, Negri D, LaBranche C *et al.* IDLV-HIV-1 Env vaccination in non-human primates
 induces affinity maturation of antigen-specific memory B cells. *Commun Biol*, 1, 134 (2018).
- Rossi A, Michelini Z, Leone P *et al.* Optimization of mucosal responses after intramuscular
 immunization with integrase defective lentiviral vector. *PLoS One*, 9(9), e107377 (2014).
- 32. Dalsgaard T, Cecchi CR, Askou AL *et al.* Improved Lentiviral Gene Delivery to Mouse Liver by
 Hydrodynamic Vector Injection through Tail Vein. *Mol Ther Nucleic Acids*, 12, 672-683 (2018).
- Jimenez DF, Lee CI, O'Shea CE, Kohn DB, Tarantal AF. HIV-1-derived lentiviral vectors and
 fetal route of administration on transgene biodistribution and expression in rhesus monkeys. *Gene Ther*, 12(10), 821-830 (2005).
- Karwacz K, Mukherjee S, Apolonia L *et al.* Nonintegrating lentivector vaccines stimulate
 prolonged T-cell and antibody responses and are effective in tumor therapy. *J Virol*, 83(7), 30943103 (2009).
- Kimura T, Koya RC, Anselmi L *et al.* Lentiviral vectors with CMV or MHCII promoters
 administered in vivo: immune reactivity versus persistence of expression. *Mol Ther*, 15(7), 13901399 (2007).
- 36. Lin YY, Belle I, Blasi M *et al.* Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective
 Lentiviral Vector-Induced Long-Term Immunity. *Mol Ther Methods Clin Dev*, 17, 532-544
 (2020).
- 780 37. Froelich S, Tai A, Wang P. Lentiviral vectors for immune cells targeting. *Immunopharmacol Immunotoxicol*, 32(2), 208-218 (2010).
- 782 38. Naldini L, Blomer U, Gallay P *et al.* In vivo gene delivery and stable transduction of nondividing
 783 cells by a lentiviral vector. *Science*, 272(5259), 263-267 (1996).

* First work to propose the use of HIV-1 derived lentiviral vector as a transfer vector for in vivo gene
delivery in non-diving cells.

- 786 39. Munis AM. Gene Therapy Applications of Non-Human Lentiviral Vectors. *Viruses*, 12(10) (2020).
- 40. Goyvaerts C, Liechtenstein T, Bricogne C, Escors D, Breckpot K. Targeted Lentiviral Vectors:
 Current Applications and Future Potential. *Gene Therapy Tools and Potential Applications*(InTech) (2013).
- 41. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear
 import is mediated by a central DNA flap. *Cell*, 101(2), 173-185 (2000).
- ** First work to establish that DNA flap is essential for HIV-1 nuclear import.
- Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. *Science*, 353(6304), 1101 1102 (2016).

- Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. *Methods Enzymol*, 346, 454-465 (2002).
- 44. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping.
 Curr Gene Ther, 5(4), 387-398 (2005).
- 45. Hacein-Bey-Abina S, von Kalle C, Schmidt M *et al.* A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med*, 348(3), 255-256 (2003).
- 46. Hacein-Bey-Abina S, Von Kalle C, Schmidt M *et al.* LMO2-associated clonal T cell proliferation
 in two patients after gene therapy for SCID-X1. *Science*, 302(5644), 415-419 (2003).
- 47. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. *Leukemia*, 32(7), 1529-1541 (2018).
- 805 48. Durand S, Cimarelli A. The inside out of lentiviral vectors. *Viruses*, 3(2), 132-159 (2011).
- 806 49. Olbrich H, Slabik C, Stripecke R. Reconstructing the immune system with lentiviral vectors. *Virus Genes*, 53(5), 723-732 (2017).
- 808 50. Banasik MB, McCray PB, Jr. Integrase-defective lentiviral vectors: progress and applications.
 809 *Gene Ther*, 17(2), 150-157 (2010).
- Saenz DT, Loewen N, Peretz M *et al.* Unintegrated lentivirus DNA persistence and accessibility
 to expression in nondividing cells: analysis with class I integrase mutants. *J Virol*, 78(6), 29062920 (2004).
- Apolonia L, Waddington SN, Fernandes C *et al.* Stable gene transfer to muscle using nonintegrating lentiviral vectors. *Mol Ther*, 15(11), 1947-1954 (2007).
- 815 53. Berger G, Goujon C, Darlix JL, Cimarelli A. SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors. *Gene Ther*, 16(1), 159-163 (2009).
- 54. Ku MW, Authié P, Bourgine M *et al.* Brain and Lung Cross-Protection against Ancestral or
 Emerging SARS-CoV-2 by Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Murine
 Model. *Research Square*, (2021).
- Ku MW, Bourgine M, Authie P *et al.* Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. *Cell Host Microbe*, 29(2), 236-249 e236 (2021).
- Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are
 actively replicating at the time of infection. *Mol Cell Biol*, 10(8), 4239-4242 (1990).
- 57. Ingusci S, Verlengia G, Soukupova M, Zucchini S, Simonato M. Gene Therapy Tools for Brain
 Diseases. *Front Pharmacol*, 10, 724 (2019).
- 58. Blasi M, Negri D, Saunders KO *et al.* Immunogenicity, safety, and efficacy of sequential
 immunizations with an SIV-based IDLV expressing CH505 Envs. *NPJ Vaccines*, 5(1), 107
 (2020).
- Blasi M, Wescott EC, Baker EJ *et al.* Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. *NPJ Vaccines*, 5(1), 36 (2020).
- Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of
 lentiviral vectors. *Hum Gene Ther*, 12(15), 1893-1905 (2001).
- 61. Counsell JR, Asgarian Z, Meng J *et al.* Lentiviral vectors can be used for full-length dystrophin gene therapy. *Sci Rep*, 7(1), 79 (2017).
- 836 62. Sweeney NP, Vink CA. The impact of lentiviral vector genome size and producer cell genomic to
 837 gag-pol mRNA ratios on packaging efficiency and titre. *Mol Ther Methods Clin Dev*, 21, 574-584
 838 (2021).
- 63. Cousin C, Oberkampf M, Felix T *et al.* Persistence of Integrase-Deficient Lentiviral Vectors
 Correlates with the Induction of STING-Independent CD8(+) T Cell Responses. *Cell Rep*, 26(5),
 1242-1257 e1247 (2019).
- 842 64. Martinez-Molina E, Chocarro-Wrona C, Martinez-Moreno D, Marchal JA, Boulaiz H. Large843 Scale Production of Lentiviral Vectors: Current Perspectives and Challenges. *Pharmaceutics*,
 844 12(11) (2020).
- 845 65. Srivastava A, Mallela KMG, Deorkar N, Brophy G. Manufacturing Challenges and Rational
 846 Formulation Development for AAV Viral Vectors. *J Pharm Sci*, 110(7), 2609-2624 (2021).
- 847 66. Vellinga J, Smith JP, Lipiec A *et al.* Challenges in manufacturing adenoviral vectors for global vaccine product deployment. *Hum Gene Ther*, 25(4), 318-327 (2014).

- Kutner RH, Puthli S, Marino MP, Reiser J. Simplified production and concentration of HIV-1based lentiviral vectors using HYPERFlask vessels and anion exchange membrane
 chromatography. *BMC Biotechnol*, 9, 10 (2009).
- 852 68. Rout-Pitt N, McCarron A, McIntyre C, Parsons D, Donnelley M. Large-scale production of
 853 lentiviral vectors using multilayer cell factories. *J Biol Methods*, 5(2), e90 (2018).
- 69. Leinonen HM, Lepola S, Lipponen EM *et al.* Benchmarking of Scale-X Bioreactor System in
 Lentiviral and Adenoviral Vector Production. *Hum Gene Ther*, 31(5-6), 376-384 (2020).
- 856 70. Valkama AJ, Leinonen HM, Lipponen EM *et al.* Optimization of lentiviral vector production for
 857 scale-up in fixed-bed bioreactor. *Gene Ther*, 25(1), 39-46 (2018).
- Ansorge S, Lanthier S, Transfiguracion J, Durocher Y, Henry O, Kamen A. Development of a
 scalable process for high-yield lentiviral vector production by transient transfection of HEK293
 suspension cultures. *J Gene Med*, 11(10), 868-876 (2009).
- 861 72. Bauler M, Roberts JK, Wu CC *et al.* Production of Lentiviral Vectors Using Suspension Cells
 862 Grown in Serum-free Media. *Mol Ther Methods Clin Dev*, 17, 58-68 (2020).
- Kesch HP, Laitinen A, Peixoto C *et al.* Production and purification of lentiviral vectors generated
 in 293T suspension cells with baculoviral vectors. *Gene Ther*, 18(6), 531-538 (2011).
- 865 74. Segura MM, Garnier A, Durocher Y, Coelho H, Kamen A. Production of lentiviral vectors by
 866 large-scale transient transfection of suspension cultures and affinity chromatography purification.
 867 *Biotechnol Bioeng*, 98(4), 789-799 (2007).
- 868 75. Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M. Continuous high-titer
 869 HIV-1 vector production. *Nat Biotechnol*, 21(5), 569-572 (2003).
- Stornaiuolo A, Piovani BM, Bossi S *et al.* RD2-MolPack-Chim3, a packaging cell line for stable
 production of lentiviral vectors for anti-HIV gene therapy. *Hum Gene Ther Methods*, 24(4), 228240 (2013).
- Tomas HA, Rodrigues AF, Carrondo MJT, Coroadinha AS. LentiPro26: novel stable cell lines for constitutive lentiviral vector production. *Sci Rep*, 8(1), 5271 (2018).
- 875 78. Manceur AP, Kim H, Misic V *et al.* Scalable Lentiviral Vector Production Using Stable
 876 HEK293SF Producer Cell Lines. *Hum Gene Ther Methods*, 28(6), 330-339 (2017).
- 877 79. Moreira AS, Cavaco DG, Faria TQ, Alves PM, Carrondo MJT, Peixoto C. Advances in Lentivirus
 878 Purification. *Biotechnol J*, 16(1), e2000019 (2021).
- 80. Dai B, Yang L, Yang H, Hu B, Baltimore D, Wang P. HIV-1 Gag-specific immunity induced by a
 lentivector-based vaccine directed to dendritic cells. *Proc Natl Acad Sci U S A*, 106(48), 2038220387 (2009).
- 81. Cire S, Da Rocha S, Yao R *et al.* Immunization of mice with lentiviral vectors targeted to MHC
 class II+ cells is due to preferential transduction of dendritic cells in vivo. *PLoS One*, 9(7),
 e101644 (2014).
- 885
 82. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family
 886 members serve as the cellular receptors for vesicular stomatitis virus. *Proc Natl Acad Sci U S A*,
 887 110(18), 7306-7311 (2013).
- 888 83. Vives RR, Lortat-Jacob H, Fender P. Heparan sulphate proteoglycans and viral vectors : ally or foe? *Curr Gene Ther*, 6(1), 35-44 (2006).
- 890 84. Goyvaerts C, De Groeve K, Dingemans J *et al.* Development of the Nanobody display technology
 891 to target lentiviral vectors to antigen-presenting cells. *Gene Ther*, 19(12), 1133-1140 (2012).
- 892 85. Funke S, Maisner A, Muhlebach MD *et al.* Targeted cell entry of lentiviral vectors. *Mol Ther*,
 893 16(8), 1427-1436 (2008).
- 894 86. Humbert JM, Frecha C, Amirache Bouafia F *et al.* Measles virus glycoprotein-pseudotyped
 895 lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic
 896 modification of monocyte-derived dendritic cells. *J Virol*, 86(9), 5192-5203 (2012).
- 87. de Swart RL, Yuksel S, Osterhaus AD. Relative contributions of measles virus hemagglutininand fusion protein-specific serum antibodies to virus neutralization. *J Virol*, 79(17), 11547-11551
 (2005).
- 900 88. Yang L, Yang H, Rideout K *et al.* Engineered lentivector targeting of dendritic cells for in vivo
 901 immunization. *Nat Biotechnol*, 26(3), 326-334 (2008).

- 90289.Hu B, Dai B, Wang P. Vaccines delivered by integration-deficient lentiviral vectors targeting903dendritic cells induces strong antigen-specific immunity. Vaccine, 28(41), 6675-6683 (2010).
- 904 90. Ageichik A, Buchholz CJ, Collins MK. Lentiviral vectors targeted to MHC II are effective in immunization. *Hum Gene Ther*, 22(10), 1249-1254 (2011).
- 906 91. Norton TD, Miller EA. Recent Advances in Lentiviral Vaccines for HIV-1 Infection. *Front* 907 *Immunol*, 7, 243 (2016).
- 908 92. Anliker B, Abel T, Kneissl S *et al.* Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. *Nat Methods*, 7(11), 929-935 (2010).
- 910 93. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. *Nat Rev* 911 *Genet*, 8(8), 573-587 (2007).
- 912 94. Hamers-Casterman C, Atarhouch T, Muyldermans S *et al.* Naturally occurring antibodies devoid
 913 of light chains. *Nature*, 363(6428), 446-448 (1993).
- 914 95. Merlin S, Follenzi A. Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors.
 915 Mol Ther Methods Clin Dev, 12, 223-232 (2019).

916 ** This review provides a comprehensive description on the usage of transcriptional and post-917 transcriptional strategies for ex vivo and in vivo gene therapy using lentiviral vectors.

- 96. Prosch S, Stein J, Staak K, Liebenthal C, Volk HD, Kruger DH. Inactivation of the very strong
 HCMV immediate early promoter by DNA CpG methylation in vitro. *Biol Chem Hoppe Seyler*,
 377(3), 195-201 (1996).
- 921 97. Liu BH, Wang X, Ma YX, Wang S. CMV enhancer/human PDGF-beta promoter for neuron922 specific transgene expression. *Gene Ther*, 11(1), 52-60 (2004).
- 923 98. Cui Y, Golob J, Kelleher E, Ye Z, Pardoll D, Cheng L. Targeting transgene expression to antigen924 presenting cells derived from lentivirus-transduced engrafting human hematopoietic
 925 stem/progenitor cells. *Blood*, 99(2), 399-408 (2002).
- 926 99. Lopes L, Dewannieux M, Gileadi U *et al.* Immunization with a lentivector that targets tumor
 927 antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. *J Virol*,
 928 82(1), 86-95 (2008).
- 929 100. Gobin SJ, Biesta P, Van den Elsen PJ. Regulation of human beta 2-microglobulin transactivation
 930 in hematopoietic cells. *Blood*, 101(8), 3058-3064 (2003).
- 931 101. van den Elsen PJ. Expression regulation of major histocompatibility complex class I and class II
 932 encoding genes. *Front Immunol*, 2, 48 (2011).
- Breckpot K, Escors D, Arce F *et al.* HIV-1 lentiviral vector immunogenicity is mediated by Tolllike receptor 3 (TLR3) and TLR7. *J Virol*, 84(11), 5627-5636 (2010).
- Brown BD, Sitia G, Annoni A *et al.* In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. *Blood*, 109(7), 2797-2805 (2007).
- 938 104. Rossetti M, Gregori S, Hauben E *et al.* HIV-1-derived lentiviral vectors directly activate
 939 plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. *Hum*940 *Gene Ther*, 22(2), 177-188 (2011).
- 941 105. Fonteneau JF, Larsson M, Beignon AS *et al.* Human immunodeficiency virus type 1 activates
 942 plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid
 943 dendritic cells. *J Virol*, 78(10), 5223-5232 (2004).
- Han P, Hanlon D, Sobolev O, Chaudhury R, Edelson RL. Ex vivo dendritic cell generation-A critical comparison of current approaches. *Int Rev Cell Mol Biol*, 349, 251-307 (2019).
- 946 107. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention
 947 strategies. *Curr Gene Ther*, 11(4), 307-320 (2011).
- 948 108. Fontana L, Nuzzo M, Urbanelli L, Monaci P. General strategy for broadening adenovirus tropism.
 949 *J Virol*, 77(20), 11094-11104 (2003).
- 950 109. Coughlan L, Alba R, Parker AL *et al.* Tropism-modification strategies for targeted gene delivery
 951 using adenoviral vectors. *Viruses*, 2(10), 2290-2355 (2010).
- 110. Kreppel F, Hagedorn C. Capsid and Genome Modification Strategies to Reduce the
 Immunogenicity of Adenoviral Vectors. *Int J Mol Sci*, 22(5) (2021).
- 111. Zaiss AK, Vilaysane A, Cotter MJ *et al.* Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. *J Immunol*, 182(11), 7058-7068 (2009).

- 956 112. Guo J, Mondal M, Zhou D. Development of novel vaccine vectors: Chimpanzee adenoviral vectors. *Hum Vaccin Immunother*, 14(7), 1679-1685 (2018).
- 113. Khare R, May SM, Vetrini F *et al.* Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. *Mol Ther*, 19(7), 1254-1262 (2011).
- 960 114. Somanathan S, Calcedo R, Wilson JM. Adenovirus-Antibody Complexes Contributed to Lethal
 961 Systemic Inflammation in a Gene Therapy Trial. *Mol Ther*, 28(3), 784-793 (2020).
- In 2 115. 2hu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Tolllike receptor-dependent and -independent pathways. *J Virol*, 81(7), 3170-3180 (2007).
- Barlan AU, Griffin TM, McGuire KA, Wiethoff CM. Adenovirus membrane penetration activates
 the NLRP3 inflammasome. *J Virol*, 85(1), 146-155 (2011).
- 966 117. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose
 967 systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized
 968 mice. *Gene Ther*, 12(5), 427-436 (2005).
- 969 118. Singh S, Kumar R, Agrawal B. Adenoviral Vector-Based Vaccines and Gene Therapies: Current
 970 Status and Future Prospects. *Adenoviruses (IntechOpen)*, (2019).
- 971 119. Milligan ID, Gibani MM, Sewell R *et al.* Safety and Immunogenicity of Novel Adenovirus Type
 972 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
 973 JAMA, 315(15), 1610-1623 (2016).
- 120. Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. *Viruses*, 13(2) (2021).
- 975 121. Sadoff J, Le Gars M, Shukarev G *et al.* Interim Results of a Phase 1-2a Trial of Ad26.COV2.S
 976 Covid-19 Vaccine. *N Engl J Med*, 384(19), 1824-1835 (2021).
- 977 122. Voysey M, Clemens SAC, Madhi SA *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
 978 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in
 979 Brazil, South Africa, and the UK. *Lancet*, 397(10269), 99-111 (2021).
- See I, Su JR, Lale A *et al.* US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. *JAMA*, 325(24), 2448-2456 (2021).
- 983 124. Gilbert SC. T-cell-inducing vaccines what's the future. *Immunology*, 135(1), 19-26 (2012).
- Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune
 complexes creates an improved environment for replication of HIV in T cells. *J Exp Med*,
 205(12), 2717-2725 (2008).
- 26. Zhu FC, Li YH, Guan XH *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet*, 395(10240), 1845-1854 (2020).
- 127. Lopez J, Anna F, Authié P *et al.* An optimized lentiviral vector induces CD4+ T-cell immunity
 and predicts a booster vaccine against tuberculosis. (*Submitted*)).
- 992 128. <u>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006260-52</u>.).
- Hu B, Tai A, Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. *Immunol Rev*, 239(1), 45-61 (2011).
- 130. Iglesias MC, Mollier K, Beignon AS *et al.* Lentiviral vectors encoding HIV-1 polyepitopes induce
 broad CTL responses in vivo. *Mol Ther*, 15(6), 1203-1210 (2007).
- 131. Negri D, Blasi M, LaBranche C *et al.* Immunization with an SIV-based IDLV Expressing HIV-1
 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. *Mol Ther*, 24(11), 2021-2032 (2016).
- 1000 132. Norton TD. Gene Therapy. *Gene Therapy*, 22, 227–236 (2015).
- 1001 133. Norton TD, Tada T, Leibowitz R, van der Heide V, Homann D, Landau NR. Lentiviral-Vector1002 Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral
 1003 Infection. *Mol Ther*, 28(8), 1795-1805 (2020).
- 1004134.Geaney DP, Soper N, Shepstone BJ, Goodwin GM, Cowen PJ. Intravenous L-tryptophan and1005regional cerebral blood flow. *Biol Psychiatry*, 29(5), 508-509 (1991).
- 1006 135. Ku MW, Anna F, Souque P *et al.* A Single Dose of NILV-Based Vaccine Provides Rapid and
 1007 Durable Protection against Zika Virus. *Mol Ther*, 28(8), 1772-1782 (2020).

* This work demonstrates that a single immunization with non-integrating LV encoding Zika premembrane envelope glycoprotein is able to provide full protection against Zika infection as early as 7
days and as durable as 6 months after immunization in mice.

- 1011136.https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006260-52.Safety,1012Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected WithHIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).).
- 1014 137. Ku MW, Authié P, Bourgine M *et al.* Full Brain and Lung Prophylaxis against SARS-CoV-2 by
 1015 Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Mouse Model or Golden Hamsters.
 1016 *BioRxiv*, (2021).
- 1017 138. Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological
 1018 Involvement in COVID-19 and Potential Mechanisms: A Review. *Neurocrit Care*, (2020).
- 1019
 139. Bourgonje AR, Abdulle AE, Timens W *et al.* Angiotensin-converting enzyme 2 (ACE2), SARS1020
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1
- 1022140.Meinhardt J, Radke J, Dittmayer C et al. Olfactory transmucosal SARS-CoV-2 invasion as a port1023of central nervous system entry in individuals with COVID-19. Nat Neurosci, 24(2), 168-1751024(2021).
- 1025141.von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain1026involvement in fatal COVID-19 outcomes. Lancet, 395(10241), e109 (2020).
- 1027 142. Alter G, Yu J, Liu J *et al.* Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. *Nature*, 596(7871), 268-272 (2021).
- 1029143.Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F. HIV-1 reverse transcription. A1030termination step at the center of the genome. J Mol Biol, 241(5), 651-662 (1994).
- 1031 144. Esslinger C, Chapatte L, Finke D *et al.* In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. *J Clin Invest*, 111(11), 1673-1681 (2003).
- 1033 145. Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK. Intravenous injection of a
 1034 lentiviral vector encoding NY-ESO-1 induces an effective CTL response. *J Immunol*, 172(3),
 1035 1582-1587 (2004).
- 146. Kim JH, Majumder N, Lin H, Watkins S, Falo LD, Jr., You Z. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. *Hum Gene Ther*, 16(11), 1255-1266 (2005).
- 1039 147. Chapatte L, Colombetti S, Cerottini JC, Levy F. Efficient induction of tumor antigen-specific
 1040 CD8+ memory T cells by recombinant lentivectors. *Cancer Res*, 66(2), 1155-1160 (2006).
- 1041148.Garcia Casado J, Janda J, Wei J *et al.* Lentivector immunization induces tumor antigen-specific B1042and T cell responses in vivo. *Eur J Immunol*, 38(7), 1867-1876 (2008).
- 1043149.Liu Y, Peng Y, Mi M et al. Lentivector immunization stimulates potent CD8 T cell responses1044against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in1045mice. J Immunol, 182(10), 5960-5969 (2009).
- 1046 * This work demonstrates that lentiviral vector immunization induced a higher magnitude of CD8⁺ T cell
 1047 response than those induced by naked DNA, expressing the same antigen. Lentiviral vector immunization
 1048 also strongly inhibits the B16 tumor growth in mice.
- 1049
 150. Adotevi O, Mollier K, Neuveut C *et al.* Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
 1051 Blood, 115(15), 3025-3032 (2010).
- 1052 151. Somaiah N, Block MS, Kim JW *et al.* First-in-Class, First-in-Human Study Evaluating LV305, a
 1053 Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY 1054 ESO-1. *Clin Cancer Res*, 25(19), 5808-5817 (2019).
- 1055 * First non-integrating lentiviral vector cancer vaccine (LV305) in clinical trial.
- 1056 152. Albershardt TC, Campbell DJ, Parsons AJ, Slough MM, Ter Meulen J, Berglund P. LV305, a
 1057 dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY 1058 ESO-1, induces potent anti-tumor immune response. *Mol Ther Oncolytics*, 3, 16010 (2016).
- 1059
 153. Pollack SM, Lu H, Gnjatic S *et al.* First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. *J Immunother*, 40(8), 302-306 (2017).

- 1062 154. Morante V, Borghi M, Farina I *et al.* Integrase-Defective Lentiviral Vector Is an Efficient Vaccine
 1063 Platform for Cancer Immunotherapy. *Viruses*, 13(2) (2021).
- 1064155.Xiao L, Joo KI, Lim M, Wang P. Dendritic cell-directed vaccination with a lentivector encoding1065PSCA for prostate cancer in mice. *PLoS One*, 7(11), e48866 (2012).
- 1066156.Deng Y, Guan J, Wen B *et al.* Induction of broadly neutralising HCV antibodies in mice by1067integration-deficient lentiviral vector-based pseudotyped particles. *PLoS One*, 8(4), e626841068(2013).
- 1069 157. Grasso F, Negri DR, Mochi S *et al.* Successful therapeutic vaccination with integrase defective
 1070 lentiviral vector expressing nononcogenic human papillomavirus E7 protein. *Int J Cancer*, 132(2),
 1071 335-344 (2013).
- * This work demonstrates that a single therapeutic immunization with non-integrative LV encoding
 HPV16 E7 is able to completely eradicate tumor in mice and can induce long lasting T cells at least up to
 one year after immunzation.
- 1075 158. Negri DR, Michelini Z, Baroncelli S *et al.* Successful immunization with a single injection of non-integrating lentiviral vector. *Mol Ther*, 15(9), 1716-1723 (2007).
- 1077 159. Asefa B, Korokhov N, Lemiale F. Heterologous HIV-based lentiviral/adenoviral vectors 1078 immunizations result in enhanced HIV-specific immunity. *Vaccine*, 28(20), 3617-3624 (2010).
- 1079
- 1080

Figure 1





Figure 2



Minus DNA strand strong stop






 Figure 4

